Abstract
The pharmaceutical industry has proven to be a somewhat fortunate anomaly over the past few years. To its left and its right - in the financial sector, the manufacturing sector and the technology sector - an increasingly demoralising war has been waged against costs. Looking to every corner of infrastructure and operations, the world seemed to hinge on streamlining processes and fighting to gain an edge that would enable another quarter of survival, however fiscally static.
| Original language | English |
|---|---|
| Pages (from-to) | 8-11 |
| Number of pages | 4 |
| Journal | European Pharmaceutical Contractor |
| Issue number | SPRING |
| Publication status | Published - Mar 2004 |
ASJC Scopus subject areas
- Pharmaceutical Science